DrugPatentWatch Database Preview

Details for Patent: 6,641,834

« Back to Dashboard

Which drugs does patent 6,641,834 protect, and when does it expire?

Patent 6,641,834 protects ALPHAGAN P and is included in two NDAs.

Protection for ALPHAGAN P has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has thirty-eight patent family members in nineteen countries.

Summary for Patent: 6,641,834

Title:	Compositions containing alpha-2-adrenergic agonist components
Abstract:	Compositions useful for improving effectiveness of alpha-2-adrenergic agonist components include carrier components, alpha-2-adrenergic agonist components, solubility enhancing components which aid in solubilizing the alpha-2-adrenergic agonist components. In one embodiment, the alpha-2-adrenergic agonist components include alpha-2-adrenergic agonists. In another embodiment, the solubility enhancing components include carboxymethylcellulose.
Inventor(s):	Olejnik; Orest (Coto de Coza, CA), Kerslake; Edward D. S. (Charlestown, MA)
Assignee:	Allergan Sales, Inc. (Irvine, CA)
Application Number:	10/236,566
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 6,641,834
Patent Claim Types: see list of patent claims	Composition; Compound;

Drugs Protected by US Patent 6,641,834

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Allergan	ALPHAGAN P	brimonidine tartrate	SOLUTION/DROPS;OPHTHALMIC	021770-001	Aug 19, 2005		RX	Yes	Yes					Y
Allergan	ALPHAGAN P	brimonidine tartrate	SOLUTION/DROPS;OPHTHALMIC	021262-001	Mar 16, 2001	AT	RX	Yes	Yes					Y

International Family Members for US Patent 6,641,834

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	033539
Australia	2001273269
Australia	2005220199
Australia	2005280259